ArticlePhysics and imaging in radiation oncology2025
Comparison of proton and photon therapy in stereotactic arrhythmia radioablation for ventricular tachycardia.
Article in Physics and imaging in radiation oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Stereotactic arrhythmia radioablation for ventricular tachycardia: Mechanisms, workflow, outcomes, and future directions.Heart rhythm O2 · 2026Review
- Stereotactic arrhythmia radioablation for refractory ventricular tachycardia: A narrative review and pooled analysis of clinical outcomes and treatment delivery approaches.Journal of applied clinical medical physics · 2026Review
- Robustness evaluation of carbon ion radiotherapy for ventricular tachycardia.Physics and imaging in radiation oncology · 2026Article
Corrections and comments
- Update of
Authors and funding
11 authors.
Funding
Abstract
Background and Purpose: Ventricular tachycardia (VT) is a life-threatening arrhythmia commonly treated with catheter ablation; however, some cases remain refractory. Stereotactic arrhythmia radioablation (STAR) offers a non-invasive alternative. While photon-based STAR is effective, proton therapy may improve dose conformity and spare critical organs at risk (OARs), including the heart itself. The aim of this study was to compare the dose-volume metrics between proton and photon therapy for VT. Materials and Methods: We retrospectively analyzed 34 VT patients who received photon STAR. Proton STAR plans were generated using robust optimization in a commercial treatment planning system to deliver the same prescription dose of 25 Gy in a single fraction. Dose-volume metrics, including Results: Proton and photon plans achieved comparable target coverage, with CTV Conclusion: Proton therapy for STAR demonstrated significant potential for OARs sparing compared to photon therapy for VT, while maintaining equivalent target coverage. These findings highlight the potential of proton therapy to improve outcomes for VT patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.